GILD GILD

Name: GILD Crucible Score
Creator: Kaladin Capital Intelligence

UnknownUnknownN/A📅 Scored March 18, 2026

Price at analysis: $137.70

Crucible Score

62.5

C+

Quality × Value Composite

KQI — Quality

64.5

B-

Fundamental Quality Index

KVI — Value

60.2

C+

Valuation Attractiveness Index

Crucible Verdict — GILD

Gilead Sciences earns a middling C+ grade, held back by weak growth prospects and limited diversification despite solid financial fundamentals. The biotech trades at a modest discount to fair value with strong earnings consistency, but GILD's reliance on mature HIV franchises and tepid pipeline development constrain upside potential. Future performance hinges on successful late-stage drug approvals.

— Kal, Kaladin Capital Intelligence

◆ KQI Quality Dimensions

Financial Quality

88.6

Growth Profile

49.8

Moat Durability

50.9

Management Effectiveness

73.4

Diversification & Resilience⚠

48.0

Market Position

59.0

Weakest dimension: Diversification & Resilience (48.0)

◆ KVI Value Dimensions

DCF Margin of Safety

61.6

FCF Yield & Cash Returns

61.3

Relative Valuation

62.3

Growth-Adjusted Value

60.2

Historical Valuation

47.4

Macro Context

66.4

◆ DCF Valuation Scenarios

Bear Case

$105.42

Base Case

$148.63

Bull Case

$207.85

Price at Analysis

$137.70

Scenario	Fair Value	Rev CAGR (5yr)	Terminal Margin	WACC
🔴 Bear	$105.42	2.0%	28.0%	6.7%
🟢 Base	$148.63	4.0%	34.0%	6.2%
🟢 Bull	$207.85	6.0%	40.0%	5.8%

Key Assumptions: WACC is low (5.8-6.7%) reflecting GILD's very low beta of 0.37 and an equity risk premium of 5.5%. Revenue growth is modest (2-6% CAGR) given GILD's mature HCV franchise offset by HIV/oncology growth from Biktarvy and Trodelvy; operating margins range from 28% (bear, reflecting generic erosion and pipeline failures) to 40% (bull, reflecting successful pipeline commercialization and Veklury stabilization). Tax rate normalized to 20% given historical volatility between 13-31%, and capex intensity held at ~2% of revenue consistent with historical levels.

◆ Financial Snapshot

Profitability

Gross Margin80.8%

Operating Margin37.4%

Net Margin28.9%

ROIC17.8%

ROE26.0%

Balance Sheet

Balance SheetCR: 1.68

Cash ConversionFCF/EPS: 1.11x

Capital IntensityCapex/Rev: 1.9%

Altman Z-Score4.22 (Safe)

Piotroski F-Score8/9 (Strong)

Growth

Revenue CAGR1.9% CAGR

Earnings CAGR8.1% CAGR

Growth ConsistencyCV: 180.84

Segment Breadth2/5 growing (40%)

Quarterly TrendMargin↑, WC↓, Exp↓

Earnings CredibilityConsistent Beater

◆ Analyst Consensus & Leadership

Leadership & Governance

CEODaniel O'Day · 8 years

CEO Ownership< 1%

Compensation88% performance-based

Insider ActivitySelling

Capital AllocationROIC 17.8% vs WACC 3.3%

Earnings Beat Rate85% (19/22)

◆ Related Companies in Our Universe

Other Unknown companies scored by the Crucible:

ADBE81.8A-NICE80.7A-DECK79.9A-INTU79.9A-EXEL78.3A-MTCH78.2A-TTD78.0B+

Methodology All Scores Crucible Briefs Performance @KaladinCI

Analysis conducted March 18, 2026 based on most recent SEC filings. Updated quarterly, after new SEC filings.

Point-in-time fundamental analysis. Not investment advice. Scores reflect company quality and valuation at time of analysis and may not reflect current market conditions.